News Sharing
For sharing news, please enter the email address of you and the receiver, then press SEND button.*Mandatory Fields
Receiver*
Enter email addresses, separated by semicolon (;). E.g. a@a.com;b@b.com
Your email address*
 Content Sharing
CANSINOBIO Completes 1st Patient Enrollment for DTcP-Hib-MCV4 Combined Vaccine
The Phase I clinical trial for the adsorbed diphtheria, tetanus and acellular pertussis (components) Haemophilus Influenzae Type b (Conjugate)-Group ACYW135 Meningococcal (Conjugat...
Reset
Send
The window will close in 5 seconds
CANSINOBIO Completes 1st Patient Enrollment for DTcP-Hib-MCV4 Combined Vaccine
Close
Recommend
4
Positive
10
Negative
2
 
SHORT SELL
 
STOCK INFO

The Phase I clinical trial for the adsorbed diphtheria, tetanus and acellular pertussis (components) Haemophilus Influenzae Type b (Conjugate)-Group ACYW135 Meningococcal (Conjugate) combined vaccine (the DTcP-Hib-MCV4 Combined Vaccine) developed by CANSINOBIO (06185.HK)  +1.160 (+3.664%)    Short selling $3.52M; Ratio 21.509%   was officially initiated recently and the first trial patient case has been formally enrolled, as announced by CANSINOBIO.

The clinical trial is designed to assess the safety and immunogenicity of the vaccine in subjects aged between 2 months to 6 years.
(HK stocks quote is delayed for at least 15 mins.Short Selling Data as at 2026-03-04 16:25.)

AAStocks Financial News
Website: www.aastocks.com
Copyright(C) AASTOCKS.com Limited 2000. All rights reserved.
Disclaimer: AASTOCKS.com Ltd, HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the Information provided but do not guarantee its accuracy or reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.